BRCA2 Genotype

This test answers a question no cholesterol panel, mammogram, or prostate test can: are you carrying an inherited flaw in one of your body's main DNA repair genes? If you are, your lifetime odds of several cancers are much higher than average, and that changes when and how closely you should be screened.

A harmful result does not mean cancer is certain. It means the odds are shifted enough that early detection and prevention can genuinely change your future, and the finding matters for your blood relatives too.

What This Gene Does

BRCA2 (breast cancer gene 2) is one of your body's DNA repair genes. It carries the instructions for a protein that fixes a specific and dangerous kind of DNA damage, the kind where both strands of the double helix snap. When you inherit a harmful version of this gene, your cells lose part of that repair ability.

Over a lifetime, unrepaired mistakes pile up, and certain tissues, especially breast, ovary, prostate, and pancreas, become far more likely to turn cancerous. This is why the same inherited change can raise risk across several different organs at once.

Breast Cancer Risk

The strongest and most consistent signal is breast cancer. In women who carry a harmful BRCA2 variant, prospective studies estimate roughly a 55% chance of breast cancer by age 70 and about 69% by age 80, well above the roughly one-in-eight lifetime risk for women overall.

The risk to the second breast after a first diagnosis is also high. One large prospective study estimated about a 26% chance of cancer in the other breast within 20 years of a first diagnosis, and another estimated the risk could reach roughly 62% by age 70 among carriers who had already been diagnosed with breast cancer, though that figure came with a wide range. Both measure risk to the second breast after a first cancer, and they use different timeframes, so they are not directly comparable. Either way, this risk is a central reason surgical and surveillance decisions differ for carriers.

Ovarian Cancer Risk

Ovarian cancer risk is lower than breast cancer risk but still far above average. Prospective studies estimate roughly 17% by age 80, and estimates across different cohorts range more widely, from about 10% to 29%. Because ovarian cancer is hard to catch early with routine testing, this number drives some of the most consequential prevention conversations for carriers.

Cancer Risk in Men

A harmful BRCA2 variant is not just a women's health issue. Male carriers face higher risks of prostate, male breast, and pancreatic cancer, and men who carry a BRCA2 variant are more likely than BRCA1 carriers to develop cancer at all, and to develop more than one primary cancer.

For prostate cancer specifically, prospective data estimate about a 27% risk by age 75 and roughly 60% by age 85 in male carriers, along with a higher chance of aggressive disease. Estimates across studies span a wider range, so these figures are best read as a central estimate rather than a fixed number. This is why targeted prostate screening starting earlier is often recommended for men who carry the variant.

Other Cancers

Beyond the core four cancers, large registry and family-based studies link harmful BRCA2 variants to elevated risk of male breast cancer, which carries one of the strongest associations, along with pancreatic and stomach cancer and melanoma. An esophageal cancer link has also been reported, but mainly from a Japanese cohort, so it may be population-specific. These associations are generally weaker than the breast and ovarian signals, but they help explain why a carrier's overall cancer surveillance plan can extend beyond a single organ.

Why Two People With a BRCA2 Variant Don't Share the Same Risk

A positive result is not a single fixed number. The specific variant, its location in the gene, your family history, and your broader genetic background all shift the estimate up or down. Understanding this keeps you from either underreacting or overreacting to the word "positive."

• Where in the gene: breast cancer risk was higher for variants falling outside one central stretch of the gene (between positions c.2831 and c.6401) than for variants inside it.
• Family history: carriers with more close relatives affected by breast cancer tend to have higher risk than carriers without that family pattern.
• Common genetic background: dozens of ordinary DNA variants add up into a polygenic score that meaningfully refines risk. Across that score, absolute ovarian cancer risk by age 80 ranged from about 6% at the low end to 19% at the high end.
• Ancestry and founder variants: specific inherited changes cluster in particular populations, such as the c.5946delT variant common in people of Ashkenazi Jewish descent, so ancestry shapes both which variant appears and how well it is understood.

When a Diagnosis Doesn't Mean a Worse Outcome

It is easy to assume that carrying a cancer gene means any cancer you get will be more deadly. The evidence does not support that simple reading, and the paradox resolves once you separate two different things: the chance of getting cancer, and how that cancer behaves if it appears. A BRCA2 variant strongly raises the first, but its effect on survival is cancer-specific.

In young-onset breast cancer, overall survival was similar for carriers and non-carriers, with any survival advantage concentrated in triple-negative disease. Prostate cancer is the clearer exception, where BRCA2 more often tracks with aggressive and metastatic disease and worse outcomes. A faulty repair gene also makes some tumors more sensitive to platinum chemotherapy and to targeted drugs called PARP inhibitors, which is why the result guides treatment, not just risk.

A One-Time Result You Act On for Life

This is a once-in-a-lifetime test. Your genotype does not change, so there is no trend to track and no reason to repeat a properly sequenced result. The value comes not from retesting the gene but from integrating the answer into decades of screening and prevention decisions.

What does need ongoing tracking is the phenotype testing a positive result unlocks. That typically means earlier and more frequent breast imaging for women, targeted prostate monitoring for men, and consideration of pancreatic and ovarian surveillance, on a schedule set with a specialist rather than by re-running the DNA test.

One caveat: a variant reported today as "uncertain" can be reclassified as evidence accumulates. If your result was an unclassified variant, it is worth asking your genetics clinician to re-review it every couple of years, because the DNA has not changed but the interpretation can.

What to Do With an Unexpected or Positive Result

A positive or unexpected result is a starting point, not a verdict. The first step is confirmation. If the result came from a consumer-style chip rather than a clinical sequencing lab, it should be verified by sequencing before it drives any decision, because chips miss most true variants and flag many false ones.

From there, the pathway is to involve a genetics clinician who can interpret the exact variant, confirm whether it is truly harmful versus uncertain, and set up companion monitoring. That usually includes breast MRI and earlier mammography for women, prostate testing for men, and discussion of ovarian and pancreatic surveillance, alongside conversations about risk-reducing options with the relevant specialists. It also means telling biological relatives, since each first-degree family member has a real chance of carrying the same variant.

When Results Can Be Misleading

Because this is a genetic test, the usual concerns about food, timing, and medications do not apply. The pitfalls are about what the assay can and cannot see, and how a variant is interpreted.

• What the panel covers: the test only detects the specific variants it is designed to find. A negative result does not rule out every rare change in the gene, and some large structural rearrangements need a separate method to detect.
• Consumer chip versus clinical sequencing: SNP chips, the technology behind many direct-to-consumer reports, are unreliable for rare harmful variants, with about 34.6% sensitivity and only a 4.2% chance that a flagged variant is real. Any positive from that source needs sequencing confirmation.
• Variants of uncertain significance: an uncertain variant is not the same as a harmful one. Most are eventually reclassified as harmless, so treating one as a confirmed high-risk result is a common and consequential error.
• Ancestry mismatch: risk estimates built mostly on European populations can be misleading for other ancestries, and non-European groups are more likely to receive uncertain or conflicting results, which is why ancestry context matters for interpretation.